Clinical Trials on Slow Virus Diseases

Total 380453 results

GlaxoSmithKline

Completed

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Drug Interaction Study With Protease Inhibitors

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
Bristol-Myers Squibb

Completed

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression (OREY)

Human Immunodeficiency Virus (HIV) Infections

Spain
Merck Sharp & Dohme LLC

Withdrawn

MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)

HIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
EMD Serono

Completed

An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome

Human Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
University of Kansas

Completed

Resistance Training and Blood Flow Restriction

Blood Flow Restriction and Low-Intensity Resistance Training

United States
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); US Military... and other collaborators

Recruiting

Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults (RV575)

Human Immunodeficiency Virus (HIV) | AIDS Virus

United States
EMD Serono

Completed

Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)

Human Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

Human Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus Prevention

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
RetroLead (Shanghai) BioPharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects

Human Immunodeficiency Virus-1 (HIV-1) Infection
Janssen R&D Ireland

Completed

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Infection, Human Immunodeficiency Virus

United States
Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
ViiV Healthcare
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)

Infection, Human Immunodeficiency Virus

Germany
ViiV Healthcare
GlaxoSmithKline

Completed

ZIAGEN® Post-marketing Surveillance

Infection, Human Immunodeficiency Virus I

Korea, Republic of
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
AbbVie (prior sponsor, Abbott)

Completed

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

Human Immunodeficiency Virus Infection
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Terminated

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) (SIGNET)

Infection, Human Immunodeficiency Virus

Spain, France, Germany
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

GSK1349572 Drug Interaction Study With Efavirenz

Infections, Human Immunodeficiency Virus and Herpesviridae

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Drug-drug Interaction (DDI) Rifabutin

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

Relative Bioavailability Study With BMS-955176

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

GSK706769 Repeat Dose Study

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

PENTA Fosamprenavir Study

Infection, Human Immunodeficiency Virus
ViiV Healthcare

Completed

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Food Effect Study With BMS-955176

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Infection, Human Immunodeficiency Virus I

United States, Spain, Canada, Russian Federation, Romania, Belgium, South Africa
ViiV Healthcare
GlaxoSmithKline

Completed

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Infections, Human Immunodeficiency Virus and Herpesviridae

United States
ViiV Healthcare
Glaxosmithkline/Quintiles

Completed

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Infection, Human Immunodeficiency Virus

United States, Canada, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

Fosamprenavir Expanded Access

Infection, Human Immunodeficiency Virus

Switzerland
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Abivax S.A.

Completed

Safety, PK and PD Study of ABX464 in Untreated HIV Patients

Human Immunodeficiency Virus Infections

Thailand, Mauritius
ViiV Healthcare
Pfizer

Withdrawn

Maraviroc Compassionate Use

Human Immunodeficiency Virus Type 1
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Canada, Portugal, Italy, Belgium
ViiV Healthcare

Completed

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

Infection, Human Immunodeficiency Virus

United States
Bristol-Myers Squibb

Completed

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat (Atazanavir)

Human Immunodeficiency Virus Type 1 (HIV-1)

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
Janssen Inc.

Completed

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients (POISE)

Human Immunodeficiency Virus (HIV)

Canada

Clinical Trials on Slow Virus Diseases

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations